Xarelto (rivaroxaban) / J&J 
Welcome,         Profile    Billing    Logout  
 97 Diseases   247 Trials   247 Trials   14602 News 


«12...3738394041424344454647...170171»
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo, Fragmin (dalteparin sodium) / Pfizer, Eisai
    Journal:  Modern anticoagulation with factor Xa inhibitors in oncology: is the gastrointestinal bleeding rate (also) decisive? (Pubmed Central) -  Jul 26, 2022   
    The FXa inhibitors are not inferior to the standard therapy with dalteparin in the VTE recurrence rate in oncological patients. The GIB rate appears to be an important predictive factor for the safety of this group of substances, so that tumor location, gastrointestinal risk factors and other individual criteria should be given greater consideration in future therapy decisions for or against an FXa inhibitor.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    PK/PD data, Review, Journal:  Population pharmacokinetic models for direct oral anticoagulants: a systematic review and clinical appraisal using exposure simulation. (Pubmed Central) -  Jul 23, 2022   
    The present results therefore question DOAC dose adaptation in the presence of these covariates such as drug-drug interaction (DDI) or genotypes alongside the known existing covariates. As the overall effect of accumulation of several covariates could be difficult to apprehend for the clinicians, POPPK modeling could represent an interesting approach for informed precision dosing and to improve personalized prescription of DOACs.
  • ||||||||||  rivaroxaban / Generic mfg., aspirin / Generic mfg., apixaban / Generic mfg.
    Journal:  Benefice and pitfall of direct oral anticoagulants in very high-risk myeloproliferative neoplasms. (Pubmed Central) -  Jul 23, 2022   
    For these high-risk patients, low-dose DOACs exposed patients to more arterial thrombosis but fewer bleeding events. Prospective studies are needed to evaluate and compare DOACs to the currently recommended antithrombotic drugs for high-risk MPN patients.
  • ||||||||||  rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg.
    Review, Journal, Adverse events:  Adverse Events of DOACs in Children. (Pubmed Central) -  Jul 23, 2022   
    This review will focus on adverse events (AEs) between specific DOACs reported in the clinical trials in children and compare them to standard of care. This will assist clinicians in decision making of selecting the right anticoagulation for their pediatric patients.
  • ||||||||||  rivaroxaban / Generic mfg., clopidogrel / Generic mfg.
    Trial completion date, Trial initiation date, Trial primary completion date, Head-to-Head:  LAAO Versus NOAC in Patients With AF and PCI (clinicaltrials.gov) -  Jul 21, 2022   
    P=N/A,  N=1386, Not yet recruiting, 
    This will assist clinicians in decision making of selecting the right anticoagulation for their pediatric patients. Trial completion date: May 2026 --> Sep 2026 | Initiation date: May 2022 --> Sep 2022 | Trial primary completion date: May 2024 --> Sep 2024
  • ||||||||||  rivaroxaban / Generic mfg.
    Trial completion, Surgery, Bariatric surgery:  ABSORB: Pharmacokinetics of Rivaroxaban After Bariatric Surgery (clinicaltrials.gov) -  Jul 21, 2022   
    P1,  N=67, Completed, 
    Trial completion date: May 2026 --> Sep 2026 | Initiation date: May 2022 --> Sep 2022 | Trial primary completion date: May 2024 --> Sep 2024 Recruiting --> Completed
  • ||||||||||  rivaroxaban / Generic mfg., enoxaparin sodium / Generic mfg., apixaban / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  Effect of Prophylactic and Therapeutic Anticoagulants in Egyptian Patients With COVID-19 (clinicaltrials.gov) -  Jul 20, 2022   
    P=N/A,  N=90, Completed, 
    Recruiting --> Completed Recruiting --> Completed | Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Apr 2021 --> Oct 2021
  • ||||||||||  Journal:  Duration of Anticoagulation Therapy in Patients with Genetic Inherited Thrombophilia. (Pubmed Central) -  Jul 20, 2022   
    Afterwards, unfractionated heparin was introduced, and then switched to enoxaparin and acenocoumarol...In the meantime, the second case, a 36 y.o. male, brother to the first patient, came with vein thrombosis of vena saphena magna of the left leg. Treatment with Acenocoumarol was started and continued for 2 years until complete resolution of the thrombi, and then it was changed to Aspirin...According to the clinical (recurrent unprovoked DVT with thromboembolic complications) and genetic testing (homozygous gene mutation for PTB) in the first patient, we decided to continue the secondary thromboprophylaxis with rivaroxaban 10 mg/day indefinitely. Testing for genetically inherited thrombophilia should be included in the risk assessment for recurrence, and performed in all patients under 50 y.o. who have a first, non-provoked episode of thrombosis, in order to determine the duration of anticoagulation therapy.
  • ||||||||||  rivaroxaban / Generic mfg., aspirin / Generic mfg.
    Trial initiation date:  Outcomes of Rivaroxaban and Aspirin in PAD After Endovascular Revascularization (clinicaltrials.gov) -  Jul 20, 2022   
    P1,  N=100, Not yet recruiting, 
    Testing for genetically inherited thrombophilia should be included in the risk assessment for recurrence, and performed in all patients under 50 y.o. who have a first, non-provoked episode of thrombosis, in order to determine the duration of anticoagulation therapy. Initiation date: May 2022 --> Aug 2022
  • ||||||||||  rivaroxaban / Generic mfg., warfarin / Generic mfg.
    Journal:  A Cohort Study on the Safety and Efficacy of Warfarin and Rivaroxaban in Anticoagulant Therapy in Patients with Atrial Fibrillation Study. (Pubmed Central) -  Jul 20, 2022   
    During the treatment, side effects such as nausea and vomiting, elevated transaminase, glutamyl transpeptidase, and diarrhea occurred between the two groups, and there was no significant difference in the number of adverse reactions between the two groups (P > 0.05). Compared with warfarin, rivaroxaban anticoagulant therapy has the same advantage in tolerance and prevention of thromboembolism in patients with AF, but rivaroxaban can effectively reduce the risk of bleeding in patients with AF.
  • ||||||||||  rivaroxaban / Generic mfg., aspirin / Generic mfg.
    Enrollment change, Trial withdrawal, Head-to-Head:  INVICTUS-ASA: INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Superiority (clinicaltrials.gov) -  Jul 19, 2022   
    P3,  N=0, Withdrawn, 
    Compared with warfarin, rivaroxaban anticoagulant therapy has the same advantage in tolerance and prevention of thromboembolism in patients with AF, but rivaroxaban can effectively reduce the risk of bleeding in patients with AF. N=2000 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  rivaroxaban / Generic mfg.
    The effectiveness of anticoagulant therapy in COVID-19 associated ischemic stroke (A2) -  Jul 18, 2022 - Abstract #EAN2022EAN_1515;    
    All anticoagulants have a significant positive effect on fibrinogen and prothrombin time, heparin and enoxyparin are effective against D-dimer, heparin and riboraxaban are effective against APTT. However, riboraxaban has almost no positive effect on D-dimer while enoxiparin has almost no positive effect on APTT.
  • ||||||||||  pegvorhyaluronidase alfa (PEGPH20) / Halozyme
    Trial completion date, Trial primary completion date, Metastases:  Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) -  Jul 18, 2022   
    P=N/A,  N=110, Active, not recruiting, 
    N=55 --> 0 | Unknown status --> Withdrawn Trial completion date: Oct 2022 --> Oct 2023 | Trial primary completion date: Oct 2022 --> Oct 2023
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Clinical, Review, Journal:  Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review. (Pubmed Central) -  Jul 17, 2022   
    Among 4191 screened publications, 35 RCTs that used dose-adjusted DOACs were identified for dabigatran, apixaban, rivaroxaban, and edoxaban...Low-intensity DOACs may be used for extended-duration treatment of VTE (apixaban and rivaroxaban), primary prevention in orthopedic surgeries (dabigatran, apixaban, and rivaroxaban), primary prevention in ambulatory high-risk cancer patients (apixaban and rivaroxaban) or (postdischarge) high-risk medical patients (rivaroxaban), in stable atherosclerotic vascular disease, or after a recent revascularization for peripheral artery disease in conjunction with aspirin (rivaroxaban)...In contrast, low-intensity DOACs may be used for primary or secondary VTE prevention for studied and approved indications. Attention should be given to routine practice patterns to align the daily clinical practice with existing evidence of safety and efficacy.
  • ||||||||||  rivaroxaban / Generic mfg., apixaban / Generic mfg.
    Journal:  Serum or Plasma for Quantification of Direct Oral Anticoagulants? (Pubmed Central) -  Jul 16, 2022   
    The choice of matrix is, thus, important when interpreting therapeutic drug monitoring results and in research involving analyses of direct oral anticoagulants. The authors recommend citrate-plasma as the preferred matrix.
  • ||||||||||  rivaroxaban / Generic mfg.
    Journal:  Changes in ocular hemodynamics in patients recovered from COVID-19 (Pubmed Central) -  Jul 16, 2022   
    There was a significant decrease in volumetric ocular blood flow parameters in COVID-19 patients who did not take any anticoagulants compared to the age-normal values. Anticoagulants intake has a positive impact on hemodynamic characteristics in the ocular vessels and volumetric ocular blood flow in patients with COVID-19.
  • ||||||||||  Journal:  Postmastectomy Breast Reconstruction is Safe in Patients on Chronic Anticoagulation. (Pubmed Central) -  Jul 15, 2022   
    Conclusion  Postmastectomy implant-based breast reconstruction can be safely performed in patients on chronic anticoagulation with appropriate perioperative management of anticoagulation. This information can be useful for preoperative counseling on these patients.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Clinical, Journal:  Comparison of Direct Oral Anticoagulants for Acute Hospital Mortality in Venous Thromboembolism. (Pubmed Central) -  Jul 15, 2022   
    On PS-matched analysis, there was a difference in in-hospital mortality, especially in the rivaroxaban and apixaban group. Identifying the clinical characteristics of patients associated with each DOAC, as well as prognosis, will be useful in determining treatment strategies for VTE.
  • ||||||||||  rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
    Retrospective data, Journal:  A Multicenter Retrospective Evaluation of Direct Oral Anticoagulants for the Treatment of Heparin-Induced Thrombocytopenia. (Pubmed Central) -  Jul 15, 2022   
    Identifying the clinical characteristics of patients associated with each DOAC, as well as prognosis, will be useful in determining treatment strategies for VTE. In this retrospective cohort study, DOACs were associated with rates of thrombotic and hemorrhagic events similar to those with other therapies currently used in the treatment of HIT.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Review, Journal:  Biopharmaceutics considerations for direct oral anticoagulants. (Pubmed Central) -  Jul 15, 2022   
    However, although there are indications of biopharmaceutics classifications for DOACs, conclusive information to classify these compounds according to the BCS is lacking, requiring more experimental studies to achieve this aim. Conclusive information is essential for a safe decision about the biowaiver, as well as to guide the development of new formulations containing the DOACs.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Trial completion date, Trial primary completion date:  ANDES: Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (clinicaltrials.gov) -  Jul 13, 2022   
    P4,  N=350, Recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Mar 2027 --> Jul 2027 | Initiation date: Mar 2022 --> Jul 2022 | Trial primary completion date: Mar 2027 --> Jul 2027 Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2022 --> Sep 2023